In addition, Ac-YVAD-CMK, a caspase-1 inhibitor, suppresses the downstream pathway of the NLRP3–caspase-1–IL-1β axis in LPS- and 6-hydroxydopamine-induced PD rats, providing a new basis for PD therapy [103]. This evidence concerns the gene NLRP3 and Parkinson disease.